3 results
Not approvedWill not start
The primary objective of the PASSENGER study is to investigate any relationship between changes in SonR1 augmentation and a change in patients* exercise capacity as assessed by the 6 Minute Walk Test.
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMORecruiting
To determine the safety, feasibility, and tolerability of adding PIPAC with oxaliplatin (92 mg/m2) to systemic chemotherapy in patients with isolated PM from CRC.